• EGF Signaling in 3D Glioblastoma Stemness Assays

  2026-09-16

  A translational framework for using recombinant human EGF as a controlled perturbation in glioblastoma spheroid assays, while distinguishing proliferation from stem-like behavior and connecting reagent quality to experimental decisions.

• Trametinib: Mapping MEK Resistance in Melanoma

  2026-09-16

  Trametinib and GSK1120212 provide precise MEK1/2 inhibition for dissecting MAPK-driven cell-state changes. This article connects pathway pharmacology with multi-omics-informed assay design for studying adaptive resistance, G1 arrest, and apoptosis in melanoma models.

• Pretomanid Targets Both TB Terminal Oxidases

  2026-09-15

  The reference study shows that pretomanid inhibits both cytochrome bcc:aa3 and cytochrome bd terminal oxidase branches in Mycobacterium tuberculosis. This dual respiratory mechanism explains synergy with telacebec and supports combination regimens designed to improve bactericidal activity while limiting resistance.

• Targeted BRD7 Demethylation in Nasopharyngeal Carcinoma

  2026-09-15

  The reference study shows that hypermethylation of the BRD7 promoter suppresses a tumor-suppressive program in nasopharyngeal carcinoma (NPC). By directing dCas9-TET1 catalytic activity to selected promoter sites, the authors reactivated BRD7 and reduced malignant progression, with combined sgRNA2 and sgRNA5 producing the strongest reported effect.

• Precision PCR for CRISPR Immunotherapy Translation

  2026-09-14

  A thought-leadership analysis of how high-fidelity PCR can strengthen translational workflows inspired by bufalin–CRISPR nanomedicine research in colorectal cancer. The article connects immune mechanism, construct integrity, blunt-end cloning, assay reproducibility, and strategic experimental design while positioning 2X HyperFusion™ High-Fidelity Master Mix as an enabling technology rather than a substitute for biological validation.

• Influenza A NEP Constraints from Mutational Scanning

  2026-09-14

  A 2025 Cell Reports study used deep mutational scanning to measure the replication effects of more than 1,800 single-amino-acid mutations in influenza A virus nuclear export protein (NEP). The work shows that the apparently disordered N-terminal domain is unusually mutation-tolerant but still influences viral RNA synthesis, host responses, and mammalian adaptation, revealing functional constraints that sequence conservation alone cannot resolve.

• Ciclesonide B3477 for Reliable Cell Assays

  2026-09-13

  Learn how Ciclesonide (SKU B3477) can improve experimental control in respiratory cell models by separating prodrug activation, glucocorticoid receptor binding, solvent handling, and biological interpretation. This scenario-driven guide links quantitative product data with practical assay design while clearly distinguishing established respiratory pharmacology from emerging ERAD research.

• Itraconazole: Mechanism, Biofilm Evidence, and Use

  2026-09-12

  Itraconazole is a triazole antifungal agent with activity against selected Candida species and important CYP3A4 interaction properties. This article separates direct itraconazole evidence from mechanistic evidence on Candida biofilm resistance and PP2A-regulated autophagy.

• Paclitaxel (Taxol): Workflow for Cancer Research

  2026-09-11

  Build more interpretable cancer assays with Paclitaxel (Taxol), from solvent-controlled microtubule stabilization to G2-M profiling and combination studies. A FOXM1-focused reference study adds a practical framework for testing whether pathway suppression can sensitize resistant models to paclitaxel.

• Ciclesonide Assays: From Prodrug to ERAD Insight

  2026-09-11

  Ciclesonide provides a powerful model for linking prodrug activation, glucocorticoid receptor binding, and lung-cell pharmacology. This article adds an assay-design framework that distinguishes validated respiratory biology from the emerging ERAD platform reported for desonide-based degraders.

• SP600125: A Practical JNK Inhibitor Workflow

  2026-09-10

  SP600125 enables mechanism-focused interrogation of JNK signaling in cytokine, inflammation, and stress-response assays. This guide connects the CPSIT_0844–TLR2/TLR4 study to practical inhibitor workflows, controls, readouts, and troubleshooting strategies.

• KPT-330: Reading XPO1–Platinum Synergy

  2026-09-10

  KPT-330 (Selinexor) links CRM1/XPO1 nuclear-export biology with platinum sensitivity. This evidence-led guide explains how recent DLBCL findings should shape mechanistic assays, controls, and interpretation in cancer research.

• ATRX-Deficient Glioma and RTK Inhibitor Sensitivity

  2026-09-09

  The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. It also shows that combining these inhibitors with Temozolomide increases toxicity in ATRX-deficient models, supporting ATRX-aware design and interpretation of glioma drug studies.

• Tetraethylammonium Chloride as a Causal Probe

  2026-09-09

  Tetraethylammonium chloride (TEAC) is more than a potassium-channel blocker: it is a causal probe for separating ion-conduction effects from downstream physiology. This article explains how to design, interpret, and limit TEAC experiments across electrophysiology, vascular research, and translational pharmacology.

• Interpretable Radiopathomics for Gastric Cancer Immunotherap

  2026-09-08

  A multicenter study developed an interpretable radiopathomics signature by integrating baseline CT images with digital H&E pathology to predict response to immunotherapy-based combination therapy in gastric cancer. The signature showed strong discrimination across internal and external cohorts and was associated with immune-regulatory biology, suggesting a route toward multimodal treatment stratification while requiring further prospective validation.

3670 records 1/245 page Next 12345 下5页 Last page